MedTrace Logo

The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects

NCT03462173 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2018-03-12

No results posted yet for this study

Summary

The Safety, Tolerability and Pharmacokinetic Study of Chronic Hepatitis C Treatment Drug Yimitasvir in Healthy Adults Subjects.

Conditions

  • Chronic Hepatitis c

Interventions

DRUG

yimitasvir

Capsule administered orally once daily

DRUG

placebo

Matching Placebo Capsule

Sponsors & Collaborators

  • Sunshine Lake Pharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yimin Cui, Doctor · Peking University First Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-12-03
Primary Completion
2015-01-30
Completion
2016-01-22

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03462173 on ClinicalTrials.gov